SCHEMBL4966772

SCHEMBL4966772

COc1cc2ncnc(N3CCC(N(C)C(=O)Nc4ccc(C(C)C)cc4)C3)c2cc1OC

nearest known ligand 0.64

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 13/20 0.64
PDGFRA P16234 5/20 0.64
KIT P10721 2/20 0.64
FLT3 P36888 2/20 0.64
JAK1 P23458 3/20 0.57
PDE3B Q13370 2/20 0.53
PDE3A Q14432 2/20 0.53
JAK2 O60674 3/20 0.53
PDE10A Q9Y233 1/20 0.53
JAK3 P52333 2/20 0.53
ENPP1 P22413 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4968165 0.90 PDGFRB (0.65) PDGFRBPDGFRAKITFLT3
SCHEMBL4969207 0.83 PDGFRB (0.66) PDGFRBPDGFRAKITFLT3PDE3B
SCHEMBL4972356 0.83 PDGFRB (0.66) PDGFRBPDGFRAKITFLT3PDE3B
SCHEMBL4965795 0.83 PDGFRB (0.66) PDGFRBPDGFRAKITFLT3PDE3B
SCHEMBL14599425 0.82 PDGFRB (0.73) PDGFRBPDGFRAKITFLT3ENPP1
SCHEMBL4971003 0.81 PDGFRB (0.71) PDGFRBPDGFRAKITFLT3PDE3B
SCHEMBL4966763 0.81 ENPP1 (0.71) PDGFRBPDGFRAKITFLT3ENPP1
SCHEMBL4966832 0.81 PDGFRB (0.71) PDGFRBPDGFRAKITFLT3ENPP1
SCHEMBL4967296 0.80 PDGFRB (0.64) PDGFRBPDGFRAKITFLT3PDE3B
SCHEMBL4965178 0.80 PDGFRB (0.64) PDGFRBPDGFRAKITFLT3PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101242838-A Synergistic modulation of FLT3 kinase using aminoquinoline and aminoquinazoline kinase modulators JANSSEN PHARMACEUTICA NV (BE) 2008-08-13 CN disclosed
EP-1899319-A2 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-19 EP disclosed
EP-1893206-A2 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-05 EP disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
WO-2006135649-A2 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
WO-2006135636-A2 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
US-20060281771-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281771-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS FLT3, CDC42BPG, PRKCQ PDGFRB 284/4885PDGFRA 460/4885KIT 197/4885
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS FLT3, BMX, ABL1 PDGFRB 51/4885PDGFRA 74/4885KIT 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.